Physician profile
Robert Glen Brown
NPI 1649051962
$1,421.99
in general payments reported to CMS, 2019-2025
15 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $132 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $379.77 | 2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $314.17 | 2024-2025 | Airsupra, Breztri, Fasenra |
| Actelion Pharmaceuticals US, INC. | $163.26 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Genzyme Corporation | $107.95 | 2024-2025 | |
| Harmony Biosciences LLC | $85.38 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $62.75 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $59.72 | 2025 | Winrevair |
| Viatris Specialty LLC | $55.95 | 2025 | Yupelri |
| Grifols USA, LLC | $49.41 | 2024-2025 | Prolastin-C Liquid |
| Insmed, INC. | $43.31 | 2025 | Brinsupri, Arikayce |
| Stryker Corporation | $30.61 | 2024 | Stryker |
| Ani Pharmaceuticals, INC. | $22.70 | 2024 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.55 | 2025 | |
| 3b Medical, INC. | $14.46 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.